Health Related Quality of Life in Pediatric Central Nervous System (CNS) Tumors: A Feasibility Study Utilizing PROMIS
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 5 - 35 |
| Updated: | 11/29/2017 |
| Start Date: | November 2014 |
| End Date: | August 2018 |
In this research study the investigators want to learn more about the quality of life before,
during and after cancer treatment in patients with central nervous system brain tumors. Often
CNS tumors and cancer treatment can cause many physical and emotional problems and side
effects. Some of these problems and treatment side effects can cause a change in a patient's
qualify of life and overall well-being. Quality of life questionnaires are used to measure
well-being and ability to carry out daily activities by asking patients to answer several
questions about their physical, emotional, and social well-being.
In this research study we want to find out if patient's answers to these questions change
over the course of your treatment. We also want to see if doctors and nurses can use these
answers to the questions to help patients feel better and increase their activity during
cancer treatment.
during and after cancer treatment in patients with central nervous system brain tumors. Often
CNS tumors and cancer treatment can cause many physical and emotional problems and side
effects. Some of these problems and treatment side effects can cause a change in a patient's
qualify of life and overall well-being. Quality of life questionnaires are used to measure
well-being and ability to carry out daily activities by asking patients to answer several
questions about their physical, emotional, and social well-being.
In this research study we want to find out if patient's answers to these questions change
over the course of your treatment. We also want to see if doctors and nurses can use these
answers to the questions to help patients feel better and increase their activity during
cancer treatment.
Pediatric CNS tumors are the second most common form of pediatric cancer and the leading
cause of death related to pediatric malignancies. Over decades of work and through the
efforts of collaborative groups, cure rates have increased significantly. However, various
types of CNS malignancy outcomes have remained stagnant. Moreover, side effects from
treatments of even the most curable CNS tumors may have dramatic short and long-term sequela
ranging from cognitive, endocrine malfunction, functional mobility, neurological, and
ophthalmologic compromises. As science and protocol directed therapies continue to find cures
for these patients, work also must continue in efforts to explore patient reported outcomes
(PROs) and health related quality of life (HRQOL) throughout the trajectory of a patient's
disease process. Increased efforts in patient reported outcomes will lead to improvements in
symptom management, functional status, and overall quality of life (QOL).
cause of death related to pediatric malignancies. Over decades of work and through the
efforts of collaborative groups, cure rates have increased significantly. However, various
types of CNS malignancy outcomes have remained stagnant. Moreover, side effects from
treatments of even the most curable CNS tumors may have dramatic short and long-term sequela
ranging from cognitive, endocrine malfunction, functional mobility, neurological, and
ophthalmologic compromises. As science and protocol directed therapies continue to find cures
for these patients, work also must continue in efforts to explore patient reported outcomes
(PROs) and health related quality of life (HRQOL) throughout the trajectory of a patient's
disease process. Increased efforts in patient reported outcomes will lead to improvements in
symptom management, functional status, and overall quality of life (QOL).
Eligibility Criteria
- Patient must have diagnosis of a CNS tumor (newly diagnosed, relapsed, refractory, or
progressed) and scheduled to receive a new therapy including surgery, chemotherapy
and/or radiation therapy.
- Age: 5 -35 years of age.
- The planned therapy must include at least one disease evaluation with the first 90
days of therapy. The patient and family must intend to return to Cincinnati Children's
Hospital at least once in the next 90 days.
- Each subject may only participate once in this study.
- The subject and/or his /her parent/guardian must be fluent in English. At the time of
study enrollment, the medical care of the subject must be managed by an attending
oncologist at Cincinnati Children's Hospital.
- The subject must have a minimum performance score of 50% (either Lansky or Karnofsky)
as documented in their medical record by clinical provider (MD or nurse practitioner).
Appendix I.
- A patient / family must be approached to participate in this study within 28 days of
the administration of the first dose of the associated therapy or surgery.
We found this trial at
1
site
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
Cincinnati, Ohio 45229
1-513-636-4200
Phone: 513-803-1126
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
Click here to add this to my saved trials
